Home  /  Resource Library  /  Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstrom macroglobulinemia: long-term follow-up

Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstrom macroglobulinemia: long-term follow-up

Long term results of a study investigating the combination of ixazomib, dexamethasone, and rituximab for first line treatment of Waldenstrom Macroglobulinemia.